Inhibiting RIP3 could protect mice against LPS-induced ARDS, at least in part, through reducing lung necrosis, decreasing inflammation and HMGB1 release in BALF, and weakening the lung neutrophil infiltration and protein leakage. Here, RIPK3 is linked to acute respiratory distress syndrome.